ImmunoGen, Inc. (NASDAQ:IMGN) shares traded -0.40% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $4.57 within the next 52-weeks. Since analyst price targets calculations are subjective, there often can be a wide range of targets from various analysts. This is the consensus price target based on the analysts polled by Thomson Reuters’ First Call as of today’s date.
In order to arrive at a price target, analysts and investors alike use various metrics to determine where the stock might be headed. One of the most common is the Price to Earnings Ratio or P/E Ratio. This is calculated by taking the current share price and dividing it by the forecasted earnings per share. As of writing, ImmunoGen, Inc. has a price to earnings ratio of N/A. Taking a step further, investors can also look to a firm’s price to earnings growth or PEG ratio. The PEG ratio represents the ratio of the price to earnings to the expected future growth rate of the company. A company with a PEG ratio greater than one might be considered overvalued using this metric alone. On the other hand if a firm has a PEG below one could be considered undervalued. A PEG that is close to one, is often considered fair value. The stock has a current PEG of 0.00.
Some other technicals to consider would be the moving averages of the company. In comparing the current price level of the equity to their moving averages, the shares are trading $0.63 off of the 50-day average of $1.88 and $0.01 away from the 200-day moving average of $2.50.
Another important factor to consider when evaluating a stock’s current and future value are the 52 week high and low levels. As of the most recent bid at the time of writing, ImmunoGen, Inc. shares are trading -78.31% away from the 52-week high mark of 11.57 and +66.23% off the 52-week bottom of 1.51.